Taysha Gene Therapies Total Current Assets 2020-2024 | TSHA

Taysha Gene Therapies total current assets from 2020 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Taysha Gene Therapies Annual Total Current Assets
(Millions of US $)
2023 $150
2022 $96
2021 $160
2020 $258
2019 $0
Taysha Gene Therapies Quarterly Total Current Assets
(Millions of US $)
2024-09-30 $162
2024-06-30 $178
2024-03-31 $131
2023-12-31 $150
2023-09-30 $172
2023-06-30 $54
2023-03-31 $72
2022-12-31 $96
2022-09-30 $43
2022-06-30 $77
2022-03-31 $107
2021-12-31 $160
2021-09-30 $197
2021-06-30 $207
2021-03-31 $240
2020-12-31 $258
2020-09-30 $279
2020-06-30
2020-03-31
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.506B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00